Company intelligence / Profile preview

Newbury Pharmaceuticals

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

Newbury Pharmaceuticals has transitioned from portfolio build-up to commercial phase. As of late 2022/early 2023:

Five products received regulatory approval in Scandinavia.
Two products launched with national tenders won.
Ongoing launches expected as more approvals are secured. The company focuses on providing cost-effective alternatives for specialty indications where branded drugs dominate the market

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecules (primarily generics and specialty drugs)
Industry: Biotech

Partnerships

Strategic partnerships for licensing/distribution with international pharma companies to bring branded generics/specialty medicines to the Nordic market. Specific partners not named publicly.

Beyond the preview

Go deeper on Newbury Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newbury Pharmaceuticals.

Explore the full profile